Nomenclature	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1328	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1329	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1330	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1331	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1332	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1333
HGNC, UniProt	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2621, http://www.uniprot.org/uniprot/P33261	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2625, http://www.uniprot.org/uniprot/P10635	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2631, http://www.uniprot.org/uniprot/P05181	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2632, http://www.uniprot.org/uniprot/P24903	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2634, http://www.uniprot.org/uniprot/P51589	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20580, http://www.uniprot.org/uniprot/Q6VVX0
EC number	http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.51 (S)‐limonene + [reduced NADPH–hemoprotein reductase] + O(2) <=> (‐)‐trans‐carveol + [oxidized NADPH–hemoprotein reductase] + H(2)O	http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1	http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1	http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1	http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1	http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.15
Inhibitors	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8777 (pIC50 7.3) [120]	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8756 (pK i 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/17125252?dopt=AbstractPlus]	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8832 (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/16495056?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2608 (pIC50 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/16495056?dopt=AbstractPlus]	–
Selective inhibitors	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8749 (pK i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/22239545?dopt=AbstractPlus]	–	–	–	–	–
Comments	Substrates include: omeprazole, proguanil, mephenytoin, diazepam [http://www.ncbi.nlm.nih.gov/pubmed/2495208?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12222994?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2291871?dopt=AbstractPlus].	Substrates include: debrisoquine, metoprolol, codeine [http://www.ncbi.nlm.nih.gov/pubmed/19102711?dopt=AbstractPlus].	Substrates: Ethanol, p‐nitrophenol [http://www.ncbi.nlm.nih.gov/pubmed/30380359?dopt=AbstractPlus].	Substrate: naphthalene [http://www.ncbi.nlm.nih.gov/pubmed/20408502?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 to 14(R)‐15(S)‐epoxyeicosatrienoic acid [http://www.ncbi.nlm.nih.gov/pubmed/8631948?dopt=AbstractPlus]. Hydroxylates albendazole[http://www.ncbi.nlm.nih.gov/pubmed/23959307?dopt=AbstractPlus]. Expressed in cardiomyocytes [http://www.ncbi.nlm.nih.gov/pubmed/29695613?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2747 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6921 [http://www.ncbi.nlm.nih.gov/pubmed/12867411?dopt=AbstractPlus].